Sruthi Narasimha Chari

Nov 4, 2024 | conexiant.com | Sruthi Narasimha Chari |Puyaan Singh |Mariam Sunny

The FDA has approved a new drug for the treatment of rosacea. The oral drug, branded Emrosi, was approved to treat inflammatory lesions associated with the disease, which mostly affects women and men in the age group of 30 to 60 years. Emrosi will be commercially available late in the first quarter or early in the second quarter of 2025, according to Journey, the drug's manufacturer. The drug, also known as DFD-29, is a low-dose minocycline, an antibiotic used for skin infections.

Oct 31, 2024 | today.westlaw.com | Sruthi Narasimha Chari |Sneha K |Shailesh Kuber |Maju Samuel

(Reuters) -Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic...

Sep 13, 2024 | yahoo.com | Bhanvi Satija |Sruthi Narasimha Chari

Bhanvi Satija and Sruthi Narasimha ChariUpdated September 13, 2024 at 5:42 PM·2 min readBy Bhanvi Satija and Sruthi Narasimha Chari(Reuters) -Independent advisers to the U.S. Food and Drug Administration said on Friday that the available data from Intercept's liver disease drug does not clearly prove its effectiveness or remove doubts about its safety, putting into question the treatment's future in the U.S. market.

Aug 14, 2024 | today.westlaw.com | Mohammed Shamsi |Sruthi Narasimha Chari |Christy Santhosh

(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Incyte's treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.

Jun 26, 2024 | reuters.com | Pratik Jain |Sruthi Narasimha Chari

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo June 26 (Reuters) - The U.S. Food and Drug Administration has granted approval to a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday. U.S.-listed shares of the company surged 11% in extended trading.